Combination therapy doubles survival in metastatic lung cancer
(NYU Langone Health / NYU School of Medicine) The immunotherapy drug pembrolizumab, combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to chemotherapy alone, according to an international, Phase III clinical trial.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Genetics | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer